Summary:
In patients with borderline coronary lesions, combined treatment with Alirocumab and Atorvastatin significantly reduced LDL-C levels, increased arterial lumen volume, and decreased plaque burden compared to Alirocumab + placebo and Atorvastatin + placebo, though it was associated with no significant adverse effects reported.
PICO | Description |
---|---|
Population | Patients (n=69) with borderline coronary lesions detected by intravascular ultrasound (IVUS), who completed a 48-week follow-up. |
Intervention | Combination therapy of Alirocumab (a PCSK9 inhibitor) and Atorvastatin. |
Comparison | Group A: Alirocumab + placebo; Group B: Atorvastatin + placebo. |
Outcome | Group C (Alirocumab + Atorvastatin) achieved the greatest LDL-C reduction (from 3.64 to 1.48 mmol/L; P < .001), significantly larger increases in arterial lumen volume (P = .038), and greater plaque volume reduction (P = .041) compared to other groups. No major side effects were reported. |
Source: Zeyu Xu, et al. “Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment.” Read article here.